|
Phase (Ph) II safety and efficacy results of a single-arm ph ib/II study of capmatinib (INC280) + gefitinib in patients (pts) with EGFR-mutated (mut), cMET-positive (cMET+) non-small cell lung cancer (NSCLC). |
|
|
Honoraria - AstraZeneca; Lilly; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche |
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD; Novartis; Pfizer; Roche |
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Novartis |
Research Funding - Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Pfizer; Samsung |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD |
Speakers' Bureau - AstraZeneca; Roche |
Research Funding - Boehringer Ingelheim; Roche |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Honoraria - Novartis; Pfizer |
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Novartis |
Research Funding - Bayer; GlaxoSmithKline; Novartis |
Travel, Accommodations, Expenses - Merck; Novartis |